|
Fort Lauderdale, FL, July 27, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions
and services announced its results of operations for the first half of fiscal 2010.
Read More
Fort Lauderdale, FL, June 1, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB)a global provider of eClinical solutions and
services, announced today that Stephen Johnson has been promoted to president and
chief operating officer. Johnson, who was most recently OmniComm’s chief operating
officer (COO) and executive vice president of business development, will continue
to oversee operations and business development, but will take on additional executive
responsibilities as well and will continue to report to chief executive officer
(CEO) Cornelis F. Wit. "Steve Johnson embodies the customer-driven focus we strive
to achieve in our company," said Mr. Wit. "His relentless pursuit of sales and marketing
opportunities and influence in helping shape the direction of the TrialMaster product
have led to significant growth opportunities for the company in the last three years."
Read More
OmniComm’s EDC System Supports Asthmatx in Gaining FDA Approval of Groundbreaking
Asthma Treatment
-TrialMaster® EDC Solution used for Collecting, Managing and Reporting
Pivotal Study Data-
Fort Lauderdale, FL, May 18, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions
announced that long-time customer, Asthmatx, Inc., Sunnyvale, Calif., received U.S.
Food and Drug Administration (FDA) approval of its Alair® Bronchial
Thermoplasty System for the treatment of severe asthma. FDA approval of the Alair
System was based on the results of the Asthma Intervention Research 2 (AIR2) Trial,
a multicenter, double-blind, sham-controlled study designed to evaluate the safety
and effectiveness of bronchial thermoplasty in adult patients with severe asthma.
The Alair System is the first device-based asthma treatment approved by the FDA.
Read More
Health Decisions Selects OmniComm Systems’ TrialMaster EDC Solution
- Adaptive CRO Implements OmniComm’s eClinical Solution to Drive Operational Efficiencies
-
Fort Lauderdale, FL, May 14, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB),a global provider of eClinical solutions,
announced that Health Decisions, a Contract Research Organization (CRO) specializing
in high-efficiency adaptive clinical trials, recently signed an agreement to utilize
OmniComm’s TrialMaster eClinical products platform.
Read More
OMNICOMM SYSTEMS, INC.® ANNOUNCES FIRST QUARTER RESULTS
- 162% Increase in New Contracts Over 2009 -
Fort Lauderdale, FL, May 14, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB),a global provider of eClinical solutions,
announced its results of operations for the first quarter of fiscal 2010.
Read More
Top-tier Medical Device Manufacturer Renews Agreement for another 5 years with
OmniComm
Fort Lauderdale, FL, March 9, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions,
announced today that a leading cardiovascular medical device manufacturer has renewed
its contract with the company for another 5 years. The agreement extends and expands
the previous five-year agreement which generated over $2.5 Million in revenue for
the company over the past three years. The company expects revenue for this customer
to increase.
Read More
OmniComm Introduces TrialOne™ - an Integrated Suite of Web Based
Solutions for Phase I Clinic Automation and Management
Fort Lauderdale, FL, March 4, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions
announced that it released TrialOne, a fully integrated, MS .NET, web-based solution
designed to automate the Phase I Clinical Trial Process. TrialOne provides all necessary
web-based tools used to recruit study volunteers, schedule screening appointments,
collect screening data, directly capture real-time data, track sample transfers
and address the unique requirements of early phase studies. Within each study, real-time
electronic data is captured and validated directly at the subject’s bedside or at
a subject queuing station. Enhanced workflow technology automates sample processing
throughout the lab. TrialOne supports a myriad of directly attached biomedical monitoring
devices such as the GE Healthcare DINAMAP® family of vital signs monitors
and various ECG devices.
Read More
OmniComm selected EDC "vendor of choice" by leading East Coast based Biotech for Phase II Central Nervous System Study
Fort Lauderdale, FL, March 3, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions,
has been selected by an east coast biotechnology company as "vendor of choice" to
perform electronic data capture (EDC) for an upcoming Phase II clinical study focusing
on a central nervous system disorder. This is a new account for OmniComm, and this
first contract is in excess of $300,000. The company believes that the client plans
to run additional studies on the TrialMaster™ platform throughout 2010.
Read More
Leading US based Pharmaceutical selects OmniComm’s TrialMaster for a Phase III
International Study
Fort Lauderdale, FL, March 2, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions,
announced today that it was selected by a leading pharmaceutical company to provide
OmniComm’s flagship EDC Solution, TrialMaster™, for a Phase III study of a drug
to test a central nervous system disorder. The contract is for in excess of $200,000
and total revenue generated from this customer exceeds $750,000 over the last six
months.
Read More
OmniComm Announces the Release of OmniConnect™ for Seamless Exchange
and Analysis of Study Data
Fort Lauderdale, FL, February 25, 2010 - OmniComm Systems, Inc.
(OTC: OMCM.OB), a global provider of eClinical solutions,
announced that it released a new Application Programming Interface (API), OmniConnect™.
OmniConnect is a REST, web services, API based on an extended CDISC ODM dataset.
The use of REST web services in the API is the first of its kind in the industry.
"This new API follows OmniComm’s continued focus on interoperability and providing
value based solutions," said Randy Smith, CTO of OmniComm Systems. "OmniConnect
brings together complex clinical trial management functionality with our TrialMaster™
EDC solution in a single, integrated database. By receiving a consistent stream
of data, TrialMaster enables sponsors and sites to take advantage of real-time integration
of disparate information and data sources."
Read More
Long Term Customers Continue to Propel OmniComm’s Fast-Paced Growth
- TrialMaster EDC Solution Selected for Enterprise-Wide Phase I Trials -
Fort Lauderdale, FL, February 23, 2010 - OmniComm Systems, Inc.
(OTC: OMCM.OB),a global provider of eClinical solutions,
announced today that a top five U.S. based Biotech Company has expanded its relationship
by signing an enterprise-wide agreement to deploy OmniComm’s TrialMaster EDC solution
for its early phase studies. The total revenue from this agreement is expected to
surpass $750,000 during its first year.
Read More
Microsoft HealthVault Connectivity Added to OmniComm’s TrialMaster™
EDC Solution
Cutting-Edge Technology Used to Link Clinical Trial and Healthcare Data
FORT LAUDERDALE, FL--(Marketwire – 1/25/10) - OmniComm Systems,
Inc. (OTC: OMCM.OB), one of the fastest growing companies in the
electronic data capture (EDC) marketplace, today announced that the company’s TrialMaster
EDC product has connected to Microsoft HealthVault. This new functionality will
streamline the information flow by enabling health records and data stored in the
patient’s HealthVault account to be transferred into TrialMaster for inclusion with
other information gathered during clinical trial participation.
Read More
OmniComm Systems’ TrialMaster™ EDC Solution Selected for Its Reputation
for Meeting Aggressive Timelines.
Ability to meet challenges of early phase requirements drives Sponsor’s decision
Fort Lauderdale, FL, December 15, 2009 - OmniComm Systems, Inc.
(OTC: OMCM.OB), one of the fastest growing companies in the
EDC marketplace, today announced that a West Coast biopharmaceutical company, who
specializes in small molecule medicines across a number of therapeutic areas, has
selected OmniComm’s TrialMaster EDC solution for conducting a Phase I study. The
9-month, 2-site study is planning to enroll over 80 subjects.
Read More
Beardsworth® Selects OmniComm Systems’ TrialMaster™ Solution
for the Electronic Data Capture (EDC) of a Phase II Vaccine Study
Fort Lauderdale, FL, November 24, 2009 - OmniComm Systems, Inc.
(OTC: OMCM.OB), one of the fastest growing companies in the
EDC marketplace, today announced that Beardsworth, a full service contract research
organization (CRO) who specializes in difficult therapeutic areas, has selected
OmniComm’s TrialMaster EDC solution for conducting a Phase II vaccine study. The
3-year, 10-site study is planning to enroll 340 subjects. "After a careful selection
process, we chose OmniComm Systems to be our preferred EDC provider," said Michael
J. O’Brien, Beardsworth President and CEO. "OmniComm’s solid reputation, early adoption
of industry standards, and the many features and benefits the platform offers, made
it a logical choice."
Read More
OmniComm Systems Continues its Rapid Expansion by Opening a New Office in Monmouth
Junction, NJ
Fort Lauderdale, FL, November 19, 2009 - OmniComm Systems, Inc.
(OTC: OMCM.OB), one of the fastest growing companies in the
EDC and eClinical marketplace, announced today that it has opened a new office in
Monmouth Junction, NJ. The new location, situated equal distance between Princeton
and Rutgers Universities, was chosen in part for its proximity to the Route One
technology and pharmaceutical research corridor.
Read More
OmniComm’s TrialMaster™ EDC Solution Selected by Leading Medical
Device Manufacturer for Phase IV Cardiovascular Device Study
Long Term Customers Continue to Propel OmniComm’s Fast-Paced Growth
Fort Lauderdale, FL, November 17, 2009 - OmniComm Systems, Inc.
(OTC: OMCM.OB), one of the fastest growing companies in the
EDC marketplace, announced today that a leader in the medical device industry has
selected OmniComm’s TrialMaster EDC solution for the data capture of a Phase IV
cardiovascular study. The 24-months, 7-site study will enroll 100 subjects.
Read More
OmniComm Ranks Number 284 on Deloitte’s 2009 Technology Fast 500™ for Fastest
Growing Companies in North America.
Attributes its 455% Percent Revenue Growth to the superiority of its Electronic Data
Capture (EDC) solution TrialMaster™ and its "First in Customer Service”
philosophy.
Fort Lauderdale, FL, October 20, 2009 - OmniComm Systems, Inc.
(OTC: OMCM.OB)today announced that it ranked number 284 on
Technology Fast 500™, Deloitte LLP’s ranking of 500 of the fastest growing technology,
media, telecommunications, life sciences and clean technology companies in North
America. Rankings are based on percentage of fiscal year revenue growth during the
five-year period from 2004–2008. OmniComm grew 455% percent during this period.
Read More
OMNICOMM DELIVERS ITS STUDY DATA TABULATION MODEL (SDTM) EXPORT TOOL AHEAD OF
ITS PLANNED 2010 RELEASE DATE.
Fort Lauderdale, FL, October 16, 2009 - /Marketwire/ OmniComm Systems,
Inc. (OTC: OMCM.OB), one of the fastest growing companies in the
electronic data capture (EDC) marketplace, announced today that its new SDTM solution
is ready, ahead of schedule, and is available to its customers for deployment and
implementation into clinical studies. This new solution was developed for OmniComm’s
flagship EDC product, TrialMaster™ and will allow for mapping and exporting of data
directly into the CDISC SDTM format, ensuring an accelerated pathway towards electronic
submission of clinical data. OmniComm is a CDISC ODM certified and is known in the
industry for its commitment to standards and for bringing innovative eClinical solution
to the life science industry. OmniComm’s TrialMaster solution has supported the
CDISC ODM, CDASH (including naming conventions and domain structures), HL7, E2B,
and caBIG standards for years, and with the addition of CDISC SDTM, will be the
first EDC company to leverage all of the industry leading standards in a single
solution.
Read More
OMNICOMM SYSTEMS' TRIALMASTER™ ADDED TO KENDLE'S SUITE OF ECLINICAL
SOLUTIONS IN MULTI-YEAR ENTERPRISE AGREEMENT.
Fort Lauderdale, FL, September 30, 2009– /Marketwire/ -- OmniComm Systems, Inc. or the "Company" (OTC Bulletin Board:
OMCM ), one of the fastest-growing companies in the EDC
marketplace, today announced that Kendle,
a leading global clinical research organization (CRO), will add OmniComm’s TrialMaster
EDC solution to its current eClinical offerings in a multi-year enterprise-wide
agreement.
Read More
OMNICOMM SYSTEMS INC. EXPANDS ITS SUCCESSFUL CRO PREFERRED PROGRAM™
BY SIGNING ON THREE NEW CRO PARTNERS.
Fort Lauderdale, FL, September 1, 2009 -- OmniComm Systems, Inc.
(OTC Bulletin Board: OMCM.OB ), a leader in integrated electronic data capture (EDC) solutions for clinical
trials, and one of the fastest growing companies in the EDC marketplace, announced
today that three additional clinical research organizations (CRO) have joined its rapidly
expanding partnership program, the CRO Preferred Program. The partnership allows
CROs in the program to offer their clients the flexible, intuitive and robust EDC
solution, TrialMaster™, for clinical trials. The CRO Preferred Program’s
distinct advantages include fixed pricing with no hidden fees, complete sales and
marketing support from OmniComm, a dedicated hosted environment and comprehensive
training and support for TrialMaster.
Read More
Pleiad Devices Selects OmniComm Systems as their eClinical Solutions Provider
Fort Lauderdale, FL, August 25, 2009 -- OmniComm Systems, Inc.
(OTC Bulletin Board: OMCM.OB ), a leader in integrated electronic data capture
(EDC) solutions for clinical trials, announced today that their EDC tool, TrialMaster™,
has been selected by Pleiad, Inc., a Cambridge, Massachusetts based Contract Research
Organization (CRO) with European operations in the U.K., to provide eClinical services
to its customers. Pleiad’s investment will provide it with the products and services
to manage two upcoming studies investigating the use of ophthalmic medical devices.
This partnership is expected to generate more than $1 million to OmniComm over the
next few years. Pleiad has worked with the TrialMaster EDC tool since April 2008
under OmniComm’s CRO Preferred Program, and is now transitioning to a Technology
Transfer model in order to provide greater value to its customers engaged in these
important clinical trials.
Read More
Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions
for International Phase III Study in Parkinson’s Disease
Fort Lauderdale, FL, August 20, 2009 -- OmniComm Systems, Inc.
(OTC Bulletin Board: OMCM.OB ), one of the fastest growing companies in the EDC
marketplace, today announced that Impax Pharmaceuticals, the brand division of Impax
Laboratories, Inc., Hayward, CA, has selected the TrialMaster EDC solution for conducting
a Phase III study in patients with Parkinson’s Disease. "While managing a global
multi site clinical trial there can be significant challenges in getting trial data
when you want it and in the format that you need it," said Suneel Gupta, PhD, Chief
Scientific Officer for Impax. "The TrialMaster EDC solution provides us with an
intuitive and easy to use export tool that simplifies the process. After considering
multiple different EDC solutions, we selected OmniComm Systems based on its customer
driven approach and reputation for delivering unparalleled service and support.
Additionally, its support of industry standards has enabled us to meet our very
tight corporate timelines for this important study."
Read More
Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for
Phase III Medical Device Study and Joins OmniComm’s CRO Preferred Program
Fort Lauderdale, FL, August 18, 2009 -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM.OB ), a leader in integrated
electronic data capture (EDC) solutions for clinical trials, announced today that it has been selected by Amarex, a
Mid-Atlantic based Contract Research Organization (CRO) to provide eClinical solutions for an upcoming Phase III
trial investigating the use of a medical device for wound healing. The study will be conducted at over 30 sites and
will recruit up to 300 patients over the course of two years. Amarex also joins OmniComm’s CRO Preferred
Program, which will allow them to offer OmniComm’s flexible, robust electronic data capture solution, TrialMaster™,
to their clients. Amarex also benefits from the CRO Program’s distinct advantages that include fixed pricing with no
hidden fees, complete sales and marketing support, and dedicated hosting services in OmniComm’s world class
hosting facility.
Read More
Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study
FT. LAUDERDALE, Fla., August 13, 2009 -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM ), a leader in integrated
electronic data capture (EDC) solutions for clinical trials, today announced that it has been selected by a leading
European based Contract Research Organization (CRO) to provide eClinical solutions for a pivotal Phase III study
in rheumatoid arthritis (RA). Phase III clinical studies serve to establish the safety and efficacy of investigational
new drugs, in large patient populations, and are the last step prior to review for approval by the regulatory
authorities, such as FDA and the EMEA . This particular RA study is expected to last 48 months and enroll close to
300 patients in 20 sites located in Europe.
Read More
Major Biotechnology Company Selects OmniComm Systems to Provide eClinical Solutions for Phase I HIV Trials
FT. LAUDERDALE, Fla., August 10, 2009 /PRNewswire-FirstCall/ -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM ), a global leader in integrated electronic data capture (EDC) solutions for clinical
trials announced today that a major West coast biopharmaceutical company has selected OmniComm to
provide eClinical solutions for two of its phase I HIV studies involving over 100 patients. Both HIV studies
are expected to run for approximately 7 months. OmniComm Systems has already done extensive work
with this client in different therapeutic areas.
Read More
OmniComm Systems Signs Licensing Deal with West Coast Clinical Research Organization
FT. LAUDERDALE, Fla., August 6, 2009 /PRNewswire-FirstCall/ --
OmniComm Systems, Inc. (OTC Bulletin Board: OMCM ), a leader in integrated electronic data capture (EDC)
solutions for clinical trials, announced today that it has entered into a licensing
agreement with a west coast Clinical Research Organization (CRO) for the use of
ther TrialMaster™ solution in a Technology Transfer model. The agreement is expected
to generate more than $1.1 million from licensing, maintenance, hosting, and consulting
fees for OmniComm over the next three years. It also allows this leading CRO to
expand its offering to its customers to include the latest in cutting edge technologies
for electronic data capture.
Read More
OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor
- Logos Technologies, Ltd.
FT. LAUDERDALE, Fla., August 4, 2009 /PRNewswire-FirstCall/ --
OmniComm Systems, Inc. (OTC Bulletin Board: OMCM ), a leader in integrated electronic data capture (EDC)
solutions for clinical trials announced today that the company has acquired the
EDC assets of UK based, clinical software provider, Logos Technologies, Ltd. The
acquisition will be operated by OmniComm’s UK subsidiary, OmniComm Ltd. Logos’ exceptional
software is used to collect clinical trial data gathered while conducting Phase
I clinical trials. Phase I clinical trials are the first stage of the US or International
regulatory approval process, in order to get new drugs and medical devices to the
marketplace. The Logos software complements OmniComm’s TrialMaster® software, which
is primarily used in later stage clinical trials. The Logos products cover all aspects
of the Phase I process from subject recruitment and clinical workflow management
to laboratory sample management. Regular EDC solutions for later stage trials do
not include a pro-active data collection system, which is imperative for the very
time-controlled data collection during many early stage clinical studies. There
are only 3 commonly known Phase I EDC systems in the world that are capable of demonstrating
this functionality.
Read More
|
